Literature DB >> 20637913

Small molecule regulators of Rb-E2F pathway as modulators of transcription.

Sandeep Singh1, Jackie Johnson, Srikumar Chellappan.   

Abstract

The retinoblastoma tumor suppressor protein, Rb, plays a major role in the regulation of mammalian cell cycle progression. It has been shown that Rb function is essential for the proper modulation of G1/S transition and inactivation of Rb contributes to deregulated cell proliferation. Rb exerts its cell cycle regulatory functions mainly by targeting the E2F family of transcription factors and Rb has been shown to physically interact with E2Fs 1, 2 and 3, repressing their transcriptional activity. Multiple genes involved in DNA synthesis and cell cycle progression are regulated by E2Fs, and Rb prevents their expression by inhibiting E2F activity, inducing growth arrest. It has been established that inactivation of Rb by phosphorylation, mutation, or by the interaction of viral oncoproteins leads to a release of the repression of E2F activity, facilitating cell cycle progression. Rb-mediated repression of E2F activity involves the recruitment of a variety of transcriptional co-repressors and chromatin remodeling proteins, including histone deacetylases, DNA methyltransferases and Brg1/Brm chromatin remodeling proteins. Inactivation of Rb by sequential phosphorylation events during cell cycle progression leads to a dissociation of these co-repressors from Rb, facilitating transcription. It has been found that small molecules that prevent the phosphorylation of Rb prevent the dissociation of certain co-repressors from Rb, especially Brg1, leading to the maintenance of Rb-mediated transcriptional repression and cell cycle arrest. Such small molecules have anti-cancer activities and will also act as valuable probes to study chromatin remodeling and transcriptional regulation.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20637913      PMCID: PMC2997897          DOI: 10.1016/j.bbagrm.2010.07.004

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  156 in total

1.  Target gene specificity of E2F and pocket protein family members in living cells.

Authors:  J Wells; K E Boyd; C J Fry; S M Bartley; P J Farnham
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

Review 2.  The E2F transcription factors: key regulators of cell proliferation.

Authors:  H Müller; K Helin
Journal:  Biochim Biophys Acta       Date:  2000-02-14

Review 3.  Chromatin modification and senescence: linkage by tumor suppressors?

Authors:  Xijing Han; Philip Berardi; Karl Riabowol
Journal:  Rejuvenation Res       Date:  2006       Impact factor: 4.663

4.  A computational genomics approach to identify cis-regulatory modules from chromatin immunoprecipitation microarray data--a case study using E2F1.

Authors:  Victor X Jin; Alina Rabinovich; Sharon L Squazzo; Roland Green; Peggy J Farnham
Journal:  Genome Res       Date:  2006-10-19       Impact factor: 9.043

5.  Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.

Authors:  Philip Kahl; Lucia Gullotti; Lukas Carl Heukamp; Susanne Wolf; Nicolaus Friedrichs; Roland Vorreuther; Gerold Solleder; Patrick J Bastian; Jörg Ellinger; Eric Metzger; Roland Schüle; Reinhard Buettner
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

Review 6.  Putting the Oncogenic and Tumor Suppressive Activities of E2F into Context.

Authors:  David G Johnson; James Degregori
Journal:  Curr Mol Med       Date:  2006-11       Impact factor: 2.222

7.  Oncogenic capacity of the E2F1 gene.

Authors:  D G Johnson; W D Cress; L Jakoi; J R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

8.  Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation.

Authors:  J F Costello; M S Berger; H S Huang; W K Cavenee
Journal:  Cancer Res       Date:  1996-05-15       Impact factor: 12.701

9.  Prohibitin requires Brg-1 and Brm for the repression of E2F and cell growth.

Authors:  Sheng Wang; Baohua Zhang; Douglas V Faller
Journal:  EMBO J       Date:  2002-06-17       Impact factor: 11.598

10.  The ErbB3 binding protein Ebp1 interacts with Sin3A to repress E2F1 and AR-mediated transcription.

Authors:  Yuexing Zhang; Damilola Akinmade; Anne W Hamburger
Journal:  Nucleic Acids Res       Date:  2005-10-27       Impact factor: 16.971

View more
  22 in total

Review 1.  E2F1: a promising regulator in ovarian carcinoma.

Authors:  Lei Zhan; Yu Zhang; Wenyan Wang; Enxue Song; Yijun Fan; Bing Wei
Journal:  Tumour Biol       Date:  2016-01-09

2.  Nicotine-mediated induction of E-selectin in aortic endothelial cells requires Src kinase and E2F1 transcriptional activity.

Authors:  Vignesh Alamanda; Sandeep Singh; Nicholas J Lawrence; Srikumar P Chellappan
Journal:  Biochem Biophys Res Commun       Date:  2012-01-03       Impact factor: 3.575

3.  Human herpesvirus 6 (HHV-6) alters E2F1/Rb pathways and utilizes the E2F1 transcription factor to express viral genes.

Authors:  Eyal Sharon; Ludmila Volchek; Niza Frenkel
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-12       Impact factor: 11.205

Review 4.  Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer.

Authors:  Kanchan Sonkar; Vinay Ayyappan; Caitlin M Tressler; Oluwatobi Adelaja; Ruoqing Cai; Menglin Cheng; Kristine Glunde
Journal:  NMR Biomed       Date:  2019-06-11       Impact factor: 4.044

Review 5.  Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.

Authors:  A R M Ruhul Amin; Phillip A Karpowicz; Thomas E Carey; Jack Arbiser; Rita Nahta; Zhuo G Chen; Jin-Tang Dong; Omer Kucuk; Gazala N Khan; Gloria S Huang; Shijun Mi; Ho-Young Lee; Joerg Reichrath; Kanya Honoki; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Bill Helferich; Chandra S Boosani; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; W Nicol Keith; Dipita Bhakta; Dorota Halicka; Elena Niccolai; Hiromasa Fujii; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang; Alan Bilsland; Dong M Shin
Journal:  Semin Cancer Biol       Date:  2015-03-06       Impact factor: 15.707

Review 6.  Transcription factor networks as targets for therapeutic intervention of cancer: the breast cancer paradigm.

Authors:  Michalis V Karamouzis; Athanasios G Papavassiliou
Journal:  Mol Med       Date:  2011-09-06       Impact factor: 6.354

7.  Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.

Authors:  Teddy S Nagaria; Julia L Williams; Charles Leduc; Jeremy A Squire; Peter A Greer; Waheed Sangrar
Journal:  Neoplasia       Date:  2013-08       Impact factor: 5.715

8.  Regulation of matrix metalloproteinase genes by E2F transcription factors: Rb-Raf-1 interaction as a novel target for metastatic disease.

Authors:  Jackie L Johnson; Smitha Pillai; Danielle Pernazza; Saïd M Sebti; Nicholas J Lawrence; Srikumar P Chellappan
Journal:  Cancer Res       Date:  2011-11-15       Impact factor: 12.701

9.  Molecular interplay between cdk4 and p21 dictates G0/G1 cell cycle arrest in prostate cancer cells.

Authors:  Thippeswamy Gulappa; Ramadevi Subramani Reddy; Suman Suman; Alice M Nyakeriga; Chendil Damodaran
Journal:  Cancer Lett       Date:  2013-05-16       Impact factor: 8.679

10.  Association between p21 Ser31Arg polymorphism and the development of cervical lesion in women infected with high risk HPV.

Authors:  Géssica Lima; Erinaldo Santos; Hildson Angelo; Micheline Oliveira; Sandra Heráclio; Fernanda Leite; Celso de Melo; Sergio Crovella; Maria Maia; Paulo Souza
Journal:  Tumour Biol       Date:  2016-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.